5 Best E-Discovery Practices in Opioid Litigation
Opioid cases bring new and unique challenges since there is an underlying national crisis that the country is in the process of combating and attempting keep people from harm.
October 03, 2019 at 07:00 AM
8 minute read
|
Since 2017, after the U.S. government declared opioid addiction a public health crisis, the courts have experienced a flood of opioid litigation cases. Opioid usage throughout America has rapidly increased and the Centers for Disease Control and Prevention estimates that opioids account for 68% all drug overdose deaths. As a result, attorneys and organizations are facing discovery challenges, which are distinct to these type of cases. Important tasks, like learning the new lingo around opioids to navigating massive data sets, can be overwhelming.
Becoming familiar with the roots of these cases and the opioid crisis in general should be the first priority in addressing litigation. Research about the opioid products that targeted organizations sell, how they reach the public, data about resulting harm and overdose/abuse trends, marketing strategies, and potential theories of liability against opioid manufacturers are all critical components to navigating complex opioid cases. By having a strong grasp on these core aspects, attorneys can create strategies for settlement negotiations, discovery, and trial.
Regardless of whether these cases settle, many cases will still advance to the discovery phase. Organizations should consider implementing the following practices to help streamline and effectively manage e-discovery in opioid litigation. These practices are important to utilize during the initial investigation stage.
1. Maintain HIPAA compliance. Pharmaceutical organizations are subject to HIPAA regulations because they store and transmit health data. The law protects personally identifiable information (PII) and protected health information (PHI) from disclosure. Failure to safeguard this type of data can incur penalties for the organization. Opioid litigation documents contain a lot of this information. As such, organizations must be familiar with the regulation's stringent security and compliance requirements. Reviewing HIPAA regulations and any applicable court decisions, along with receiving continuous training, are key to successful HIPAA compliance.
Next, organizations must have a protocol to protect PII and PHI from getting into the public domain. In the realm of e-discovery, this means redacting all HIPAA-covered data from document disclosure. Explore different tools that can automate data identification in order to simplify the redaction process and make it more efficient. Also, ensure that all applications subject to disclosure have redaction capabilities. For example, a discovery request may ask for data in its original format. If the original format was stored on an excel sheet, make sure to redact the health data within that application, as opposed to converting it to a word document. If an organization releases HIPAA-covered data, there are serious consequences.
2. Utilize review technology. Opioid litigation involves reviewing massive data sets. Discovery requests will likely target specialized information that could be lost in a sea of pharmaceutical data containing unique terms of art. Automated review technology is necessary to help streamline litigation and yield efficient results while meeting strict deadlines. Using predictive coding tools will create legally defensible and thorough processes that demonstrably reduce costs, while enhancing accuracy and consistency. For example, technology-assisted review (TAR) solutions have superior categorization capabilities based on a document training set. TAR can recognize relevant data and prioritize the most responsive documents for manual review. The TAR process helps eliminate less responsive documents that would waste the reviewer's time and money while adding no value to e-discovery compliance efforts and litigation strategy.
Continuous active learning (CAL) is currently the most sophisticated type of predictive coding technology. CAL can review data on a rolling basis, which is beneficial in an opioid litigation setting where new evidence can pop up frequently. Using this type of technology early on is helpful to get to the heart of the case, which then allows litigators to manage expectations, refine strategy, and advance settlement discussions. Other beneficial features of CAL include metrics reports, redaction assistance, and data organization. The benefits of using advanced technology with TAR capabilities in opioid litigation are paramount and produce improved outcomes.
3. Implement sound data security practices. Due to the increased amount of PII and PHI opioid litigation documents contain, safeguarding sensitive data is a top priority. Privacy obligations extend to anyone involved in the case—attorneys, support staff, clients, experts, courts, or third-party vendors. Organizations housing the sensitive data involved in these cases are higher risk targets for cyberattacks and should review internal and vendor security systems, protocols, and policies. When collecting e-discovery data in opioid litigation, organizations must know which data sets potentially contain sensitive information and take extra protective measures.
Security options can include encryption, VPN usage, multi-factor authentication, firewalls, intrusion detection software, restricted Internet/device access, enhanced building/device security, and using secured networks. Additional best security practices include updating obsolete systems and policies, performing continuous vulnerability assessments and remediation, offering regular security awareness training, and only using e-discovery vendors that employ superior security safeguards with the proper certifications. All of these actions help minimize the risk of losing, exposing, or compromising the sensitive data encountered in opioid litigation.
While taking these steps will help prevent a breach in most situations, cyberattacks and data-breaches can unfortunately still occur. To prepare for these situations and limit the fallout, organizations should have an incident response plan that outlines how to stop active breaches and mitigate damages. The response plan should identify the roles the e-discovery team members and determine what type of opioid litigation data is sensitive to breaches. Organizing training opportunities and mock data breach scenarios also helps prepare teams for potential attacks. If a breach compromises any sensitive information, organizations must act fast to save the data and notify affected individuals when mandated. Taking these measures will help prevent delays in the opioid litigation as well as reduce the risk of new litigation stemming from a data breach.
4. Become educated about relevant search criteria. Opioid litigation brings new types of technical language that lawyers may not understand. Working with pharmaceutical experts is crucial in order to learn the appropriate terms of art and identify which search criteria will yield relevant content. Consultation and collaboration between field experts and litigation teams will ensure that searches are effective.
To make these searches effective, the process will require both initial training and continuous review. A good practice is to create a search criterion manual containing all relevant terms, definitions, and their significance in opioid litigation cases. Organizations should also consider having their experts review e-discovery requests and responses before disclosure to ensure they have identified all relevant data and fully complied with the request.
5. Obtain forensic expertise. Data collection in an opioid case involves unique pharmaceutical data types like prescriptions, complex databases, development testing, and research studies. The data comes in many formats, is stored in several places, and can be both structured and unstructured. The majority of data will be nontraditional and require specialized collection methods and consultants that have forensic expertise in this field. Practitioners must first identify who has custody of the data and then determine appropriate collection methods. If using third-party vendors or consultant services, make sure their methods are secure (as discussed above). When requesting, collecting, or reviewing discovery data, it is important to focus the scope and identify trends in order to obtain the most relevant information.
The data review phase also entails transforming raw data into meaningful information that can support the case. In an opioid case, some common practices can include comparing data back-ups from different periods to prove that data points related to a test were manipulated or converting individual data points to aggregate totals in order to pinpoint trends. Results from marketing studies, product testing, and prescription trends could also be relevant to these cases and may require data transformation in order for the data to make sense and support case arguments.
|Conclusion
Applying the above e-discovery habits to opioid litigation practice will help litigators gain a competitive edge and manage their cases more efficiently. Opioid cases bring new and unique challenges since there is an underlying national crisis that the country is in the process of combating and attempting keep people from harm. Keeping protected data safe from disclosure or cyberattacks at every stage of the process is of critical importance to avoid HIPAA violations and other liability. Using advanced review technology and consulting field experts crucial to getting a grasp on the case, promoting settlement negotiations, and maintaining e-discovery compliance. Taking these extra steps will undoubtedly create improved outcomes and make the process smoother.
Samantha Green, Esq. serves as the Manager of Thought Leadership for Epiq, in which capacity she serves as a subject matter expert on all aspects of electronic discovery and data privacy law, drawing on her more than fifteen years of litigation and consulting experience.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View AllTrending Stories
- 1Litera Acquires Document Automation Startup Offices & Dragons
- 2Patent Trolls Come Under Increasing Fire in Federal Courts
- 3Transforming Dispute Processes in Law: The Impact of Large Language Models
- 4Daniel Habib to Serve as Next Attorney-in-Charge of NY Federal Defender Appeals Unit
- 5Protecting Attorney-Client Privilege in the Modern Age of Communications
Who Got The Work
Michael G. Bongiorno, Andrew Scott Dulberg and Elizabeth E. Driscoll from Wilmer Cutler Pickering Hale and Dorr have stepped in to represent Symbotic Inc., an A.I.-enabled technology platform that focuses on increasing supply chain efficiency, and other defendants in a pending shareholder derivative lawsuit. The case, filed Oct. 2 in Massachusetts District Court by the Brown Law Firm on behalf of Stephen Austen, accuses certain officers and directors of misleading investors in regard to Symbotic's potential for margin growth by failing to disclose that the company was not equipped to timely deploy its systems or manage expenses through project delays. The case, assigned to U.S. District Judge Nathaniel M. Gorton, is 1:24-cv-12522, Austen v. Cohen et al.
Who Got The Work
Edmund Polubinski and Marie Killmond of Davis Polk & Wardwell have entered appearances for data platform software development company MongoDB and other defendants in a pending shareholder derivative lawsuit. The action, filed Oct. 7 in New York Southern District Court by the Brown Law Firm, accuses the company's directors and/or officers of falsely expressing confidence in the company’s restructuring of its sales incentive plan and downplaying the severity of decreases in its upfront commitments. The case is 1:24-cv-07594, Roy v. Ittycheria et al.
Who Got The Work
Amy O. Bruchs and Kurt F. Ellison of Michael Best & Friedrich have entered appearances for Epic Systems Corp. in a pending employment discrimination lawsuit. The suit was filed Sept. 7 in Wisconsin Western District Court by Levine Eisberner LLC and Siri & Glimstad on behalf of a project manager who claims that he was wrongfully terminated after applying for a religious exemption to the defendant's COVID-19 vaccine mandate. The case, assigned to U.S. Magistrate Judge Anita Marie Boor, is 3:24-cv-00630, Secker, Nathan v. Epic Systems Corporation.
Who Got The Work
David X. Sullivan, Thomas J. Finn and Gregory A. Hall from McCarter & English have entered appearances for Sunrun Installation Services in a pending civil rights lawsuit. The complaint was filed Sept. 4 in Connecticut District Court by attorney Robert M. Berke on behalf of former employee George Edward Steins, who was arrested and charged with employing an unregistered home improvement salesperson. The complaint alleges that had Sunrun informed the Connecticut Department of Consumer Protection that the plaintiff's employment had ended in 2017 and that he no longer held Sunrun's home improvement contractor license, he would not have been hit with charges, which were dismissed in May 2024. The case, assigned to U.S. District Judge Jeffrey A. Meyer, is 3:24-cv-01423, Steins v. Sunrun, Inc. et al.
Who Got The Work
Greenberg Traurig shareholder Joshua L. Raskin has entered an appearance for boohoo.com UK Ltd. in a pending patent infringement lawsuit. The suit, filed Sept. 3 in Texas Eastern District Court by Rozier Hardt McDonough on behalf of Alto Dynamics, asserts five patents related to an online shopping platform. The case, assigned to U.S. District Judge Rodney Gilstrap, is 2:24-cv-00719, Alto Dynamics, LLC v. boohoo.com UK Limited.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250